An Extension Multicenter Phase II Open Label Non-Comparative Trial of RP56976 Administered Every Three Weeks in Combination With Daily Prednisolone for Metastatic Hormone Refractory Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2015
At a glance
- Drugs Docetaxel (Primary) ; Prednisolone
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Sanofi
- 20 May 2009 Actual patient number (16) added as reported by ClinicalTrials.gov.
- 16 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Aug 2008 New trial record.